From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Webinar March 19, 2024 at 1:00 PM EST
Manufacturer portfolios are becoming more diversified in terms of product archetypes. Outside of traditional retail brands, traditional syndicated data sources are losing coverage and accuracy as a demand source. 867 data that is carefully stewarded and unblinded can fill enormous gaps for vaccines, specialty lite, specialty HCP admin, bio similars, and specialty generics. In this session, we will discuss different use cases, key stakeholders, and business benefits of enriched 867 data.
Join Emily Mortimer and Samer Allabadi on March 19 to learn more!
Emily MortimerExecutive Director, Customer Operations
Samer AllabadiSenior Director, Channel and Patient Advisory
